Welcome to our dedicated page for HEALTHTECH SOLUTIONS news (Ticker: HLTT), a resource for investors and traders seeking the latest updates and insights on HEALTHTECH SOLUTIONS stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HEALTHTECH SOLUTIONS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HEALTHTECH SOLUTIONS's position in the market.
Healthtech Solutions Inc. (OTC PINK:HLTT) has acquired 51% of World Reach Holdings, LLC, enhancing its marketing and distribution capabilities in the healthtech sector. The undisclosed cash and stock transaction strengthens Healthtech's portfolio, which includes patented wound care products like DermaBind. With World Reach's established network, the company aims to expand its global sales, especially to U.S. government and private sectors. The acquisition enables joint marketing of new products, such as EnduraKit, and supports future growth. Healthtech's two newly acquired laboratories in Salt Lake City enhance its diagnostic capabilities, with expectations for increased revenue and profit.
Healthtech Solutions, Inc. (OTC: HLTT) appointed Paul Mann to its Board of Directors as part of its strategy to enhance its portfolio-model life sciences approach. Mann, who has over 20 years of experience in finance and biotechnology, previously chaired Varian Biopharmaceuticals and served as CFO at PolarityTE. His expertise in evaluating healthcare investments is expected to strengthen Healthtech's mission to build impactful solutions across its subsidiary companies. CEO Ned Swanson emphasized Mann's valuable insights will propel the company towards its objectives.
Healthtech Solutions, Inc. (OTC: HLTT) has appointed Steve Horowitz to its Board of Directors as of July 8, 2021. Horowitz, currently the Global Tax Director at DiazReus International Law Firm, brings extensive experience in business advisory and financial analysis. His previous roles include Managing Member at Horowitz & Rubenstein, LLC, and Horowitz Consulting Group, LLC. CEO Ned Swanson expressed excitement regarding Horowitz’s strategic legal and financial insights, which aim to support Healthtech’s mission of advancing healthcare and benefiting patients.
Healthtech Solutions has announced the appointment of Brad K. Mathis as Chief Operating Officer and Ryan Salomone to its Board of Directors. Mathis brings over 30 years of experience in the pharmaceutical and biotech sectors, having held key positions at Argenx and Alexion. Salomone, with over 15 years at Fidelity Institutional Asset Management, adds valuable healthcare investment expertise. Their appointments are expected to enhance Healthtech's capabilities in developing innovative healthcare solutions, contributing to both patient outcomes and investor value.
Healthtech Solutions, Inc. (OTC: HLTT) has appointed Dr. Edward (Ned) Swanson as its new Chief Executive Officer. Dr. Swanson is a co-founder of PolarityTE and brings extensive experience in building public companies and leading biotech initiatives. His background includes leadership roles at PolarityTE and a residency in plastic surgery at Johns Hopkins. Chairman David Rubin highlighted Swanson's success in medical bioengineering and public company management, anticipating that his leadership will promote growth and shareholder value. Dr. Swanson aims to drive innovative biotech technologies to market.
Healthtech Solutions, Inc. (OTC: HLTT) announces its acquisition of Healthtech Oncology, Inc., which will hold a 100% interest in Varian Biopharmaceuticals Inc., a company focused on developing innovative cancer treatments. Varian is advancing a proprietary atypical protein kinase C iota inhibitor targeting various tumors, including basal cell carcinoma and non-small cell lung cancer. As the precision oncology market is projected to grow significantly, HLTT's move aligns with its strategy of investing in cutting-edge healthcare technologies.
Healthtech Solutions, Inc. (OTC: HLTT) filed a Reg A with the SEC on March 8, 2021, aiming to raise up to $75 million by offering 1.5 million shares of Series B preferred stock at $50 each. The funds will support growth initiatives including the commercialization of a cloud-based ultrasound software and the development of therapies for various medical conditions. Medi-Scan has created software that enhances ultrasound imaging, while RevHeart is advancing cardiomyopathy detection and treatment technologies, having filed a provisional patent for its innovations.
Healthtech Solutions, Inc. (OTC: HLTT) has launched a new subsidiary, RevHeart, Inc., to further research and develop treatments for COVID-related heart muscle injuries. With a focus on identifying myocardial deformities, RevHeart aims to implement therapies for myocardial damage recovery. A provisional patent application has been filed for a method that combines stem cell and electromagnetic field therapies. The recent merger with Medi-Scan is expected to enhance the company's access to capital and healthcare opportunities.
FAQ
What is the market cap of HEALTHTECH SOLUTIONS (HLTT)?
